NO20032482D0 - Compounds specific for adenosine A1, A2A and A <N> 3 receptor, and use thereof - Google Patents
Compounds specific for adenosine A1, A2A and A <N> 3 receptor, and use thereofInfo
- Publication number
- NO20032482D0 NO20032482D0 NO20032482A NO20032482A NO20032482D0 NO 20032482 D0 NO20032482 D0 NO 20032482D0 NO 20032482 A NO20032482 A NO 20032482A NO 20032482 A NO20032482 A NO 20032482A NO 20032482 D0 NO20032482 D0 NO 20032482D0
- Authority
- NO
- Norway
- Prior art keywords
- adenosine
- receptor
- compounds specific
- compounds
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20032482D0 true NO20032482D0 (en) | 2003-06-02 |
NO20032482L NO20032482L (en) | 2003-07-28 |
NO327207B1 NO327207B1 (en) | 2009-05-11 |
Family
ID=27419112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032482A NO327207B1 (en) | 2000-12-01 | 2003-06-02 | Compounds specific for adenosine A1, A2A and A3 receptor as well as their use in the preparation of drugs and methods for the preparation of the compounds |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1347980A4 (en) |
JP (1) | JP4579497B2 (en) |
CN (1) | CN1263757C (en) |
AP (1) | AP1893A (en) |
AU (1) | AU2002248151B2 (en) |
BR (1) | BR0115847A (en) |
CA (1) | CA2430577A1 (en) |
CZ (1) | CZ20031831A3 (en) |
EA (1) | EA007254B1 (en) |
HU (1) | HUP0400692A3 (en) |
IL (1) | IL155962A0 (en) |
ME (1) | MEP35308A (en) |
MX (1) | MXPA03004717A (en) |
NO (1) | NO327207B1 (en) |
NZ (1) | NZ525885A (en) |
OA (1) | OA13295A (en) |
PL (1) | PL363245A1 (en) |
WO (1) | WO2002057267A1 (en) |
YU (1) | YU42703A (en) |
ZA (1) | ZA200303729B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
HUP0103836A3 (en) | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
DE10148883A1 (en) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors |
EP2050751A1 (en) | 2001-11-30 | 2009-04-22 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
JP2005516005A (en) * | 2001-12-07 | 2005-06-02 | バーテクス ファーマスーティカルズ インコーポレイテッド | Pyrimidine-based compounds useful as GSK-3 inhibitors |
DE60236458D1 (en) | 2001-12-20 | 2010-07-01 | Osi Pharm Inc | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONISTIC COMPOUNDS, THEIR SYNTHESIS AND USE |
EP1465631B1 (en) | 2001-12-20 | 2010-02-24 | OSI Pharmaceuticals, Inc. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
US7199119B2 (en) * | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (en) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES |
ES2878130T3 (en) | 2006-04-25 | 2021-11-18 | Astex Therapeutics Ltd | Derivatives of purine and deazapurine as pharmaceutical compounds |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
BRPI0818533B8 (en) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | compound, pharmaceutical composition, use of a compound, and, process for preparing a compound |
US8349847B2 (en) | 2008-01-11 | 2013-01-08 | Durga Prasad Konakanchi | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents |
AR070127A1 (en) | 2008-01-11 | 2010-03-17 | Novartis Ag | PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS |
RS59568B1 (en) | 2011-04-01 | 2019-12-31 | Astrazeneca Ab | Therapeutic treatment |
EP2785349B2 (en) | 2011-11-30 | 2022-11-09 | Astrazeneca AB | Combination treatment of cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
MX2014014832A (en) * | 2012-06-07 | 2015-02-12 | Hoffmann La Roche | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase. |
BR112015031073B1 (en) | 2013-06-21 | 2022-11-29 | Zenith Epigenetics Ltd | BICYCLIC BROMODIMANIUM INHIBITORS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS |
CN105473581B (en) * | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | The dicyclic compound newly replaced as bromine structural domain inhibitor |
WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
EP3230277B1 (en) | 2014-12-11 | 2019-09-18 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
WO2016097863A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Inhibitors of bromodomains |
EA036122B1 (en) * | 2015-01-20 | 2020-09-30 | Уси Форчун Фармасьютикал Ко., Лтд | Jak inhibitor |
PT3290418T (en) | 2015-04-29 | 2019-07-16 | Wuxi Fortune Pharmaceutical Co Ltd | Janus kinase (jak) inhibitors |
EP3305788B1 (en) | 2015-05-29 | 2020-08-05 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase inhibitor |
CN105771672B (en) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method |
CN108570054B (en) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application |
CN108017584B (en) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3Small molecule antagonists of adenosine receptors |
EP3802540A1 (en) * | 2018-06-04 | 2021-04-14 | Exscientia Ltd | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
CN110128316B (en) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | Preparation method of 5-substituted beta-proline and derivatives thereof |
CN110272373B (en) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | Selective adenosine A 1 Receptor antagonists and uses thereof |
CN114085178A (en) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ286892B6 (en) * | 1992-12-17 | 2000-07-12 | Pfizer | Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
HUP0103836A3 (en) * | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
ES2269217T3 (en) * | 1999-12-02 | 2007-04-01 | Osi Pharmaceuticals, Inc. | SPECIFIC COMPOUNDS FOR ADENOSINE A1, A2A AND A3 RECEPTORS AND THEIR USES. |
EP2050751A1 (en) * | 2001-11-30 | 2009-04-22 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
-
2001
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 IL IL15596201A patent/IL155962A0/en unknown
- 2001-11-30 YU YU42703A patent/YU42703A/en unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/en unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/en not_active Application Discontinuation
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/en unknown
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/en active IP Right Grant
- 2001-11-30 EA EA200300628A patent/EA007254B1/en not_active IP Right Cessation
- 2001-11-30 CN CNB018224601A patent/CN1263757C/en not_active Expired - Fee Related
- 2001-11-30 PL PL01363245A patent/PL363245A1/en not_active Application Discontinuation
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/en unknown
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/en not_active Expired - Fee Related
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2002248151B2 (en) | 2008-02-21 |
PL363245A1 (en) | 2004-11-15 |
HUP0400692A2 (en) | 2004-07-28 |
EA200300628A1 (en) | 2003-12-25 |
EA007254B1 (en) | 2006-08-25 |
EP1347980A4 (en) | 2005-02-09 |
CN1263757C (en) | 2006-07-12 |
AP2003002807A0 (en) | 2003-06-30 |
CZ20031831A3 (en) | 2004-05-12 |
IL155962A0 (en) | 2003-12-23 |
MXPA03004717A (en) | 2004-06-30 |
JP2004517896A (en) | 2004-06-17 |
EP1347980A1 (en) | 2003-10-01 |
NZ525885A (en) | 2005-01-28 |
WO2002057267A1 (en) | 2002-07-25 |
ZA200303729B (en) | 2004-05-14 |
CN1489590A (en) | 2004-04-14 |
MEP35308A (en) | 2011-02-10 |
NO20032482L (en) | 2003-07-28 |
AP1893A (en) | 2008-09-23 |
HUP0400692A3 (en) | 2007-09-28 |
CA2430577A1 (en) | 2002-07-25 |
YU42703A (en) | 2006-03-03 |
NO327207B1 (en) | 2009-05-11 |
OA13295A (en) | 2007-04-13 |
BR0115847A (en) | 2004-02-25 |
JP4579497B2 (en) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20032482L (en) | Compounds specific for adenosine A1, A2A and A <N> 3 receptor, and use thereof | |
PT1056759E (en) | 2- (PURIN-9-YL) -TETRAHYDROFURANE-3,4-DIOLE DERIVATIVES | |
ATE256141T1 (en) | N-PYRAZOLE A2A RECEPTOR AGONISTS | |
DE60002722D1 (en) | C-PYRAZOLE A2A RECEPTOR AGONISTS | |
MA26878A1 (en) | ADENOSINE RECEPTOR REGULATORS | |
NO20032735L (en) | Diphenyllazetidinone derivatives, process for their preparation, drugs containing these compounds and their use | |
EE200000441A (en) | 2- (purin-9-yl) tetrahydrofuran-3,4-diol derivatives | |
DE60110219D1 (en) | ADENOSINE A2A RECEPTOR ANTAGONISTS | |
NO20022573D0 (en) | N6 heterocyclic, 8-modified adenosine derivatives | |
MXPA03000078A (en) | Purine derivatives. | |
PT1192170E (en) | PROPARGILFENILETER A2A RECEPTOR AGONISTS | |
DE60209251D1 (en) | ADENOSINE A2A RECEPTOR ANTAGONISTS | |
DE69934814D1 (en) | NON-CIRCULAR MICRO-DRILLING | |
NO20032483L (en) | Condensed purine derivatives as A <N> 1 <N /> - adenosine receptor antagonists | |
ID28539A (en) | IMIDAZO (1,2A) AZINA SUBSTITUTED AS A COX-2 SELECTIVE HOLDER | |
AU2001247227A1 (en) | 2-thioether a2a receptor agonists | |
ATE308460T1 (en) | TRANSFER MECHANISM | |
IT247521Y1 (en) | PANIC HANDLE. | |
IT247441Y1 (en) | PANIC HANDLE. | |
GB0010292D0 (en) | A adenosine receptor agonists | |
IT1308149B1 (en) | MODIFIED TOOL HOLDER. | |
ES1030353Y (en) | HAND FOR MORTAR, IMPROVED. | |
ZA200204153B (en) | Compounds specific to adenosine A3, A2A, and A3 receptor and uses thereof. | |
ES1040494Y (en) | ISOTHERMIC BAG FOR BOTTLES. | |
ES1041367Y (en) | DEVICE FOR HOLDING PANELS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |